Compare Incyte Corporation (INCY) vs Lowe`s Companies Inc (LOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Lowe`s Companies Inc — how do they compare? Incyte Corporation trades at $117 (market cap $23.11B), while Lowe`s Companies Inc trades at $203.77 (market cap $114.78B). The key difference: Lowe`s Companies Inc is far larger — about 5× Incyte Corporation's market cap, and Lowe`s Companies Inc pays a 2.44% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | LOW | |
|---|---|---|
Market Cap | $23.11B | $114.78B |
Sector | Health | Consumer Cyclical |
52-Week High | $118.52 | $287.39 |
52-Week Low | $67.38 | $204.76 |
Enterprise Value | $19.13B | $156.54B |
Dividend Yield | — | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $117.39, up 0.12% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $112.78. The company reported strong Q1 2026 earnings of $1.81 per share, beating expectations, and maintains robust profitability with a net income margin of 26.71%. Recent developments include a collaboration with Halozyme for cancer therapy and positive regulatory updates for Opzelura in Europe.
Outlook remains positive driven by earnings growth and pipeline advancements, though risks include competitive pressures and reliance on key products. The stock offers potential upside to the high target of $140, supported by institutional interest and solid cash flow generation, but investors should monitor execution on upcoming Q2 results.
Lowe's Companies (LOW) trades at $203.52, down 2.5% over the past day, amid a bearish technical signal. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS expected at $4.26. Revenue declined to $83.67 billion in 2025, but net income margin remains healthy at 7.51%. Analyst consensus is strongly bullish with a $260.88 price target, though technical indicators show selling pressure and support near $196.
LOW presents a mixed outlook: strong fundamentals and analyst support contrast with near-term technical weakness. Upside potential exists if earnings momentum continues and interest rate declines benefit home improvement spending. Key risks include revenue volatility, high debt levels, and competitive pressures. The stock's current dip may offer a buying opportunity for long-term investors, contingent on macroeconomic stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →
